Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

  1. Weisel, Katja
  2. Spencer, Andrew
  3. Lentzsch, Suzanne
  4. Avet-Loiseau, Hervé
  5. Mark, Tomer M.
  6. Spicka, Ivan
  7. Masszi, Tamas
  8. Lauri, Birgitta
  9. Levin, Mark-David
  10. Bosi, Alberto
  11. Hungria, Vania
  12. Cavo, Michele
  13. Lee, Je-Jung
  14. Nooka, Ajay
  15. Quach, Hang
  16. Munder, Markus
  17. Lee, Cindy
  18. Barreto, Wolney
  19. Corradini, Paolo
  20. Min, Chang-Ki
  21. Chanan-Khan, Asher A.
  22. Horvath, Noemi
  23. Capra, Marcelo
  24. Beksac, Meral
  25. Ovilla, Roberto
  26. Jo, Jae-Cheol
  27. Shin, Ho-Jin
  28. Sonneveld, Pieter
  29. Casneuf, Tineke
  30. DeAngelis, Nikki
  31. Amin, Himal
  32. Ukropec, Jon
  33. Kobos, Rachel
  34. Mateos, Maria-Victoria

Download
s13045-020-00948-5.pdf 883,30KB
WeightNameValue
1000 Titel
  • Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
1000 Autor/in
  1. Weisel, Katja |
  2. Spencer, Andrew |
  3. Lentzsch, Suzanne |
  4. Avet-Loiseau, Hervé |
  5. Mark, Tomer M. |
  6. Spicka, Ivan |
  7. Masszi, Tamas |
  8. Lauri, Birgitta |
  9. Levin, Mark-David |
  10. Bosi, Alberto |
  11. Hungria, Vania |
  12. Cavo, Michele |
  13. Lee, Je-Jung |
  14. Nooka, Ajay |
  15. Quach, Hang |
  16. Munder, Markus |
  17. Lee, Cindy |
  18. Barreto, Wolney |
  19. Corradini, Paolo |
  20. Min, Chang-Ki |
  21. Chanan-Khan, Asher A. |
  22. Horvath, Noemi |
  23. Capra, Marcelo |
  24. Beksac, Meral |
  25. Ovilla, Roberto |
  26. Jo, Jae-Cheol |
  27. Shin, Ho-Jin |
  28. Sonneveld, Pieter |
  29. Casneuf, Tineke |
  30. DeAngelis, Nikki |
  31. Amin, Himal |
  32. Ukropec, Jon |
  33. Kobos, Rachel |
  34. Mateos, Maria-Victoria |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-08-20
1000 Erschienen in
1000 Quellenangabe
  • 13(1):115
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s13045-020-00948-5 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439722/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM).!##!Methods!#!This subgroup analysis evaluated D-Vd versus Vd in CASTOR based on cytogenetic risk, determined using fluorescence in situ hybridization and/or karyotype testing performed locally. High-risk patients had t(4;14), t(14;16), and/or del17p abnormalities. Minimal residual disease (MRD; 10!##!Results!#!After a median follow-up of 40.0 months, D-Vd prolonged median PFS versus Vd in patients with standard (16.6 vs 6.6 months; HR, 0.26; 95% CI, 0.19-0.37; P < 0.0001) and high (12.6 vs 6.2 months; HR, 0.41; 95% CI, 0.21-0.83; P = 0.0106) cytogenetic risk. D-Vd achieved deep responses, including higher rates of MRD negativity and sustained MRD negativity versus Vd, regardless of cytogenetic risk. The safety profile was consistent with the overall population of CASTOR.!##!Conclusion!#!These updated data reinforce the effectiveness and tolerability of daratumumab-based regimens for RRMM, regardless of cytogenetic risk status.!##!Trial registration!#!ClinicalTrials.gov, NCT02136134 . Registered 12 May 2014.
1000 Sacherschließung
lokal Multiple myeloma
lokal Aged, 80 and over [MeSH]
lokal Multiple Myeloma/pathology [MeSH]
lokal Aged [MeSH]
lokal Bortezomib/administration
lokal Progression-Free Survival [MeSH]
lokal Myeloma therapy
lokal Multiple Myeloma/genetics [MeSH]
lokal Risk [MeSH]
lokal Male [MeSH]
lokal Antibodies, Monoclonal/administration
lokal Dexamethasone/administration
lokal Multiple Myeloma/drug therapy [MeSH]
lokal Female [MeSH]
lokal Follow-Up Studies [MeSH]
lokal Adult [MeSH]
lokal Kaplan-Meier Estimate [MeSH]
lokal Humans [MeSH]
lokal Middle Aged [MeSH]
lokal Abnormal Karyotype [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Recurrence [MeSH]
lokal Clinical trials
lokal Research
lokal Neoplasm, Residual [MeSH]
lokal In Situ Hybridization, Fluorescence [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/V2Vpc2VsLCBLYXRqYQ==|https://frl.publisso.de/adhoc/uri/U3BlbmNlciwgQW5kcmV3|https://frl.publisso.de/adhoc/uri/TGVudHpzY2gsIFN1emFubmU=|https://frl.publisso.de/adhoc/uri/QXZldC1Mb2lzZWF1LCBIZXJ2w6k=|https://frl.publisso.de/adhoc/uri/TWFyaywgVG9tZXIgTS4=|https://frl.publisso.de/adhoc/uri/U3BpY2thLCBJdmFu|https://frl.publisso.de/adhoc/uri/TWFzc3ppLCBUYW1hcw==|https://frl.publisso.de/adhoc/uri/TGF1cmksIEJpcmdpdHRh|https://frl.publisso.de/adhoc/uri/TGV2aW4sIE1hcmstRGF2aWQ=|https://frl.publisso.de/adhoc/uri/Qm9zaSwgQWxiZXJ0bw==|https://frl.publisso.de/adhoc/uri/SHVuZ3JpYSwgVmFuaWE=|https://frl.publisso.de/adhoc/uri/Q2F2bywgTWljaGVsZQ==|https://frl.publisso.de/adhoc/uri/TGVlLCBKZS1KdW5n|https://frl.publisso.de/adhoc/uri/Tm9va2EsIEFqYXk=|https://frl.publisso.de/adhoc/uri/UXVhY2gsIEhhbmc=|https://frl.publisso.de/adhoc/uri/TXVuZGVyLCBNYXJrdXM=|https://frl.publisso.de/adhoc/uri/TGVlLCBDaW5keQ==|https://frl.publisso.de/adhoc/uri/QmFycmV0bywgV29sbmV5|https://frl.publisso.de/adhoc/uri/Q29ycmFkaW5pLCBQYW9sbw==|https://frl.publisso.de/adhoc/uri/TWluLCBDaGFuZy1LaQ==|https://frl.publisso.de/adhoc/uri/Q2hhbmFuLUtoYW4sIEFzaGVyIEEu|https://frl.publisso.de/adhoc/uri/SG9ydmF0aCwgTm9lbWk=|https://frl.publisso.de/adhoc/uri/Q2FwcmEsIE1hcmNlbG8=|https://frl.publisso.de/adhoc/uri/QmVrc2FjLCBNZXJhbA==|https://frl.publisso.de/adhoc/uri/T3ZpbGxhLCBSb2JlcnRv|https://frl.publisso.de/adhoc/uri/Sm8sIEphZS1DaGVvbA==|https://frl.publisso.de/adhoc/uri/U2hpbiwgSG8tSmlu|https://frl.publisso.de/adhoc/uri/U29ubmV2ZWxkLCBQaWV0ZXI=|https://frl.publisso.de/adhoc/uri/Q2FzbmV1ZiwgVGluZWtl|https://frl.publisso.de/adhoc/uri/RGVBbmdlbGlzLCBOaWtraQ==|https://frl.publisso.de/adhoc/uri/QW1pbiwgSGltYWw=|https://frl.publisso.de/adhoc/uri/VWtyb3BlYywgSm9u|https://frl.publisso.de/adhoc/uri/S29ib3MsIFJhY2hlbA==|https://frl.publisso.de/adhoc/uri/TWF0ZW9zLCBNYXJpYS1WaWN0b3JpYQ==
1000 Hinweis
  • DeepGreen-ID: b20f5aa8ae324fe6bff8e584e73bd2e2 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6463059.rdf
1000 Erstellt am 2023-11-15T16:19:11.134+0100
1000 Erstellt von 322
1000 beschreibt frl:6463059
1000 Zuletzt bearbeitet 2023-11-30T20:57:01.653+0100
1000 Objekt bearb. Thu Nov 30 20:57:01 CET 2023
1000 Vgl. frl:6463059
1000 Oai Id
  1. oai:frl.publisso.de:frl:6463059 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source